Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Exagen (XGN) EBT (2018 - 2026)

Exagen filings provide 9 years of EBT readings, the most recent being -$3.9 million for Q1 2026.

  • On a quarterly basis, EBT fell 4.77% to -$3.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$20.1 million, a 29.58% decrease, with the full-year FY2025 number at -$19.9 million, down 31.76% from a year prior.
  • EBT hit -$3.9 million in Q1 2026 for Exagen, up from -$4.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$3.0 million in Q2 2024 to a low of -$15.1 million in Q4 2022.
  • Median EBT over the past 5 years was -$5.0 million (2024), compared with a mean of -$6.5 million.
  • Biggest five-year swings in EBT: tumbled 128.86% in 2022 and later skyrocketed 65.83% in 2023.
  • Exagen's EBT stood at -$15.1 million in 2022, then skyrocketed by 63.35% to -$5.5 million in 2023, then soared by 32.33% to -$3.7 million in 2024, then decreased by 24.3% to -$4.7 million in 2025, then rose by 15.64% to -$3.9 million in 2026.
  • The last three reported values for EBT were -$3.9 million (Q1 2026), -$4.7 million (Q4 2025), and -$7.1 million (Q3 2025) per Business Quant data.